Forget This Biotech Stock’s Rally Signals Fresh Jump
NovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
See what results to expect from zero based budgeting and how to monitor progress with clear, actionable metrics.
19,375 articlesNovaGen Therapeutics rockets after a major AI-driven deal, highlighting a rare biotech upside amid a cooling AI market.
BlackBerry reports three profitable quarters powered by QNX, but Wall Street shows little enthusiasm as shares hover ...
As markets swing in early 2026, many investors pay active fees for funds that closely track benchmarks. Here’s a fast...
AI stocks have run hot, but some Wall Street analysts see big downside. Here are two names in the artificial intellig...
Webull’s March-quarter results reveal a bold pivot: the CEO says B2B revenue could rival or surpass retail in the com...
Analysts lift HIMS, TDOC, and ALEC as strategic partnerships reduce key risks, prompting renewed upside potential and...
A leading infrastructure stock surged 124% in the past year, even as a major fund dumped roughly $38 million of its s...
Is Bloom Energy a buy, sell, or hold in 2026? This guide breaks down the business, potential catalysts, and key risks...
A veteran Wall Street analyst sees Delta Air Lines climbing roughly 50% in 2026, backed by fuel-efficiency gains and ...
As allogene (allo) 2025 earnings loom, investors weigh pipeline progress, collaboration milestones, and cash runway. ...
As markets brace for a mid-month catalyst, March 16 could be a pivotal moment. This guide breaks down the drivers, sc...
ServiceNow faces AI disruption head-on, arguing its execution platform creates a durable moat even as shares slide. C...